INSMInsmed Incorporated

1. Oct 5, 2026On October 5, 2026, Insmed Incorporated (the “Company”) announced that Sara Bonstein, the Company’s Chief Financial Officer, would be separating from the Company, effective October 30, 2026, and the Company has a search underway to identify a successor.Director or officer change · Form 8-K
2. Aug 6, 2026Insmed Reports Second-Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
3. Jul 16, 2026Insmed Announces Positive 12-Month Data from the Ongoing Open-Label Extension Study of Treprostinil Palmitil Inhalation Powder (TPIP) in Patients.Regulation FD disclosure · press release
4. May 7, 2026Insmed Reports First-Quarter 2026 Financial Results and Provides Business Update.Earnings release · press release
5. Apr 7, 2026On April 7, 2026, the Company issued a press release announcing topline efficacy and safety results from its Phase 2b CEDAR study of brensocatib in patients with HS. The CEDAR study was a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of brensocatib in adults with moderate to …Regulation FD disclosure · Form 8-K
6. Mar 23, 2026On March 23, 2026, the Company issued a press release announcing positive topline results from the ENCORE Study.Regulation FD disclosure · Form 8-K
7. Feb 19, 2026On February 17, 2026, David W.J. McGirr notified the board of directors (the “Board”) of the Company that he will not stand for re-election to the Board upon the expiration of his current term as a Class II director, which will occur at the Company’s 2026 Annual Meeting of Shareholders (the “Annual Meeting”)Earnings release · Form 8-K
8. Jan 9, 2026Insmed Provides Business Update at 44th Annual J.P. Morgan Healthcare Conference.Regulation FD disclosure · press release
9. Dec 17, 2025On December 17, 2025, the Company issued a press release announcing topline efficacy and safety results from the Phase 2b BiRCh study of brensocatib for patients with CRSsNP. The BiRCh study was a randomized, double-blind, parallel-group, placebo-controlled, multicenter study to evaluate the efficacy and safety of …Regulation FD disclosure · Form 8-K
10. Nov 18, 2025On November 18, 2025, the Company announced that the EC has approved BRINSUPRI (brensocatib 25 mg tablets) for the treatment of NCFB in patients 12 years of age and older with two or more exacerbations in the prior 12 months.Regulation FD disclosure · Form 8-K
11. Oct 30, 2025Insmed Reports Third-Quarter 2025 Financial Results and Provides Business Update.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.